Ignite Creation Date:
2024-05-06 @ 6:43 PM
Last Modification Date:
2024-10-26 @ 2:53 PM
Study NCT ID:
NCT05752851
Status:
RECRUITING
Last Update Posted:
2023-03-03
First Post:
2023-02-21
Brief Title:
The Alteration of Gut Microbiota and Analysis of Related Factors in Newly Diagnosed Type 2 Diabetes Patients
Sponsor:
Nanjing First Hospital Nanjing Medical University
Organization:
Nanjing First Hospital Nanjing Medical University
Study Overview
Official Title:
Nanjing First HospitalNanjing Medical University
Status:
RECRUITING
Status Verified Date:
2023-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This Study aims to compare the characteristics of gut microbiota between the newly diagnosed T2DM and healthy subjects and analysis the related clinical indicators that may affect the composition of gut microbiota
Detailed Description:
Previous studies have shown that gut microbiota imbalance is closely related to a variety of diseases such as inflammatory bowel diseases IBD colorectal cancer CRC Alzheimers disease AD and cardiovascular diseases In recent years more and more studies have found that gut microbiota plays an important role in chronic metabolic diseases such as obesity fatty liver and diabetes gut microbiota disorder may lead to insulin resistancepancreatic islets injury and disorder of glycolipid metabolism through multiple metabolic pathways such as endotoxin short chain fatty acids bile acids amino acids promote the occurrence and development of T2DM At present there are relatively few population-based studies to assess the relationship between gut microbiota and diabetes and the results are inconsistent or even contradictory which may be due to the influence of the research population disease status diet drugs and even detection technology Therefore the purpose of this study is to explore the difference of intestinal microbial characteristics between the initially diagnosed T2DM and the control group by using 16S rRNA gene sequencing analysis technology so as to increase the understanding of the possible relationship between T2DM and intestinal microbiota and provide theoretical support and direction guidance for the future biological treatment of diabetes
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None